- Home
- ESTA vs GHRS Comparison
ESTA vs GHRS Comparison
Compare ESTA & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESTA
- GHRS
- Stock Information
- Founded
- ESTA 2004
- GHRS 2018
- Country
- ESTA Costa Rica
- GHRS Ireland
- Employees
- ESTA N/A
- GHRS N/A
- Industry
- ESTA Industrial Specialties
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- ESTA Health Care
- GHRS Health Care
- Exchange
- ESTA Nasdaq
- GHRS Nasdaq
- Market Cap
- ESTA 982.3M
- GHRS 849.8M
- IPO Year
- ESTA 2018
- GHRS 2021
- Fundamental
- Price
- ESTA $43.58
- GHRS $12.66
- Analyst Decision
- ESTA Buy
- GHRS Strong Buy
- Analyst Count
- ESTA 6
- GHRS 8
- Target Price
- ESTA $55.50
- GHRS $30.63
- AVG Volume (30 Days)
- ESTA 377.8K
- GHRS 176.0K
- Earning Date
- ESTA 08-05-2025
- GHRS 05-08-2025
- Dividend Yield
- ESTA N/A
- GHRS N/A
- EPS Growth
- ESTA N/A
- GHRS N/A
- EPS
- ESTA N/A
- GHRS N/A
- Revenue
- ESTA $170,235,000.00
- GHRS N/A
- Revenue This Year
- ESTA $27.10
- GHRS N/A
- Revenue Next Year
- ESTA $24.55
- GHRS N/A
- P/E Ratio
- ESTA N/A
- GHRS N/A
- Revenue Growth
- ESTA 9.27
- GHRS N/A
- 52 Week Low
- ESTA $26.56
- GHRS $6.00
- 52 Week High
- ESTA $52.41
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- ESTA 66.96
- GHRS 49.08
- Support Level
- ESTA $34.34
- GHRS $11.50
- Resistance Level
- ESTA $43.45
- GHRS $12.54
- Average True Range (ATR)
- ESTA 2.06
- GHRS 0.83
- MACD
- ESTA 0.44
- GHRS -0.12
- Stochastic Oscillator
- ESTA 89.24
- GHRS 17.09
About ESTA Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.